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AnticancerThe expression of epidermal growth factor receptor (EGFR) across a wide range of tumor cells has
attracted attention for use as a tumor marker in drug delivery systems. Therefore, binding molecules with
the ability to target EGFR have been developed. Among them, we focused on affibodies that are binding
proteins derived from staphylococcal protein A. By displaying affibody (ZEGFR) binding to EGFR on the sur-
face of a bio-nanocapsule (BNC) derived from a hepatitis B virus (HBV), we developed an altered BNC
(ZEGFR-BNC) with a high specificity to EGFR-expressing cells. We considered two different types of
ZEGFR (Z955 and Z1907), and found that the Z1907 dimer-displaying BNC ([Z1907]2-BNC) could effectively
bind to EGFR-expressing cells and deliver drugs to the cytosol. Since this study showed that [Z1907]2-
BNC could target EGFR-expressing cells, we would use this particle as a drug delivery carrier for various
cancer cells expressing EGFR.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Epidermal growth factor receptor (EGFR) is a transmembrane
protein belonging to the ErbB receptor kinase family.1 EGFR regu-
lates important signals in intracellular processes such as prolifera-
tion, apoptosis, differentiation and migration via activation of the
intracellular tyrosine kinase domain due to dimerization triggered
by binding with ligands.2–4 Over-expressing EGFR is detected in a
wide range of tumors such as cell lung cancer, esophageal cancer,
gastric cancer, pancreas cancer, and kidney cancer, which makes
it an attractive target of molecular imaging and treatment.5,6
Methods that can be used to target EGFR-expressing tumors
have been studied, and the best-known targeting agents are mon-
oclonal antibodies against EGFR. These agents are often used in
receptor inhibitors that cause internalization of ligand-binding
sites and decrease the available EGFR on the cell surface.7 Recent
reports have focused on binding proteins called affibodies that
are based on the Z domain derived from staphylococcal protein
A.8 Affibodies have a binding ability that is similar to that of anti-
bodies, and they are small (monomer; 7 kDa and dimer; 15 kDa)
with an easy expression that is due to a lack of cysteine. Affibodies
consist of 58 amino acid residues with three a helix structures.
Various affibodies with different specificities were developed byrandomizing 13 amino acids during the first and second of three
a helixes.9 Among them, Z955 and Z1907 are known as affibodies
(ZEGFR) with specificity to EGFR. The binding ability is KD = 185 nM
and KD = 5.4 nM, respectively, and the dimer formulate is reported
to result in an increased binding ability ([Z955]2; KD = 50 nM).10,11
A bio-nanocapsule (BNC) that is composed of the L protein of
the hepatitis B virus (HBV) surface antigen (HBsAg) and a lipid
bilayer shows high specificity for human hepatocytes.12 Therefore,
BNCs have been studied as a possible drug delivery system (DDS)
that can incorporate drugs and genes.13 Several varieties of speci-
ficity-altered BNCs have been generated by deleting the hepato-
cyte-specific recognition site (located in the preS region) in the L
protein and inserting binding molecules with the ability to target
other cells. For example, a BNC with a ZZ domain14 (dimer of Z
domain derived from Staphylococcal protein A) inserted will bind
to the Fc region of immunoglobulin G (IgG). Also, the insertion of
biotin15 permits the recognition of various types of cells through
streptavidin and biotinylated antibodies that bind to receptors.
Furthermore, we have developed a BNC displaying affibody, ZHER2
(Z342), which has the ability to specifically bind to HER2.16,17 How-
ever, while full-length antibody-displaying BNCs14 and heavy-
chain antibody-displaying BNCs15 mediated by the ZZ domain
and the biotin–streptavidin interaction, respectively have already
been reported as carriers targeting EGFR, a ZEGFR-displaying BNC
has not been developed yet. The advantage of this particle is that
we can get the binding molecules-displaying particles without
addition and fusion of them later on. To recognize target cells,
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streptavidin or streptavidin fused with binding molecules and ZZ
domain-displaying BNC needs antibodies with Fc region. Although
these particles have the advantages that they could change target
cells by altering the kind of binding molecules, it would be thought
that they have the demerits such as expansion of particle diameter,
variation in amount of binding molecules on the particle surface
and desorption of binding molecules in the blood. Therefore, it
would be thought that this approach can be the best possible
option in the case of EGFR-targeting BNCs. In this study, we devel-
oped two types of ZEGFR-displaying BNC that display Z955 or Z1907
with differing affinity for EGFR on the particle surface and demon-
strated the binding ability to EGFR-expressing cells.
We prepared [dimer of ZEGFR]-displaying BNC, [Z955]2-BNC and
[Z1907]2-BNC, from S. cerevisiae AH22R harboring the plasmids
pGLDsLd50-[Z955]218 and pGLDsLd50-[Z1907]2,19 respectively, as
described previously.12
First, in order to check the expressions of each L protein
inserted into the dimers of Z955 or Z1907 in S. cerevisiae, we per-
formed western blot analysis20 (Fig. 1B). Since the desired bands
appeared at about 45 kDa, the expressions of L protein inserted
into the dimers of Z955 or Z1907 were confirmed. The band
(<37 kDa) for [Z955]2-BNC was thought to be the S protein fusing
the monomer of Z955.
Second, to examine each [ZEGFR]2-BNC-formed particle struc-
ture, we measured the particle diameters via dynamic light scatter-
ing (DLS) using a Zetasizer Nano ZS (Malvern Instruments,
Worcestershire, UK) (Fig. 1C). The diameters of [Z955]2-BNC and
[Z1907]2-BNC were 127 and 86 nm, respectively. We determined
that [ZEGFR]2-BNC formed the conventional particle size appropri-
ate for a drug delivery system (<200 nm).
To demonstrate cell-specificity to EGFR-expressing cells21 for
[ZEGFR]2-BNC, Alexa Fluor 488-labeled22 [Z955]2-BNC and
[Z1907]2-BNC were added to EGFR-positive HeLa cells,23 A431
cells, and EGFR-negative MCF-7 cells.24 After incubation for 3 h,Fig. 1. Construction and characterization of ZEGFR-BNCs. (A) amino acid sequence of ZWT,
(left image) and [Z1907]2-BNC (right image) were analyzed with anti-protein A antibodwe measured the fluorescent intensity of these cells via flow
cytometry25 (Fig. 2). The addition of each particle promoted clear
fluorescence for HeLa and A431 cells in a dose-dependent manner,
while it never exhibited fluorescence for MCF-7 cells. This result
indicated that [Z955]2-BNC and [Z1907]2-BNC specifically targeted
EGFR-expressing cells, and [Z1907]2-BNC showed an ability to rec-
ognize EGFR-expressing cells that was higher than that of [Z955]2-
BNC.
Then, to demonstrate the internalization of Alexa Fluor 488-
labeled [Z1907]2-BNC showing high cell-specificity, we observed
the time course of internalization to EGFR-positive HeLa and
EGFR-negative MCF-7 cells using LSCM26 (Fig. 3). Binding to the
cell membranes of HeLa was observed after incubation for
30 min, and the internalization into HeLa cells was observed after
incubation for 120 min. Additionally, it was confirmed that
[Z1907]2-BNC had the ability of cell specificity, because neither
binding nor internalization were observed for MCF-7 after incuba-
tion for 180 min.
To release drugs into the cytosol following cellular uptake, we
confirmed whether it would be possible to grant the ability of
endosomal escape to [Z1907]2-BNC by forming a complex with
LP containing 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(DOPE), which is a helper lipid that enhances fusing with the endo-
somal membrane via the pH response. We prepared a complex car-
rier ([Z1907]2-BNC/LP) encapsulating green fluorescence calcein.27
Then, we added a particle to EGFR-expressing HeLa cells and
observed the time course of endosomal escape using LSCM28
(Fig. 4). This merge is the image overlapping the green fluorescence
of calcein and the red fluorescence of endosome stained with Lyso-
Tracker, and the merge shows a yellow color if calcein is localized
in the endosome. Since the merge image after incubation for 3 h
showed yellow endosomes, this indicated that calcein was located
in the endosomes. However, after incubation for 24 h, there were
cells with green fluorescent cytosol due to the endosomal escape
of calcein. This result indicated that [Z1907]2-BNC/LP gained theZ955 and Z1907. (B) Western blotting analyses of ZEGFR-BNCs. Purified [Z955]2-BNC
y. (C) Size distribution using DLS analysis.
Fig. 2. Dose dependence of [ZEGFR]2-BNCs into (A) HeLa, (B) A431 and (C) MCF-7 cells. Cells were incubated with Alexa Fluor 488-labeled [Z955]2-BNC (white bars) and
[Z1907]2-BNC (gray bars) (final concentration: 0.5–2.5 lg/ml) for 3 h.
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ery into the cytosol of EGFR-expressing cells.
Since it was indicated that [Z1907]2-BNC/LP could release drugs
into the cytosol, we demonstrated that [Z1907]2-BNC/LP encapsu-
lating doxorubicin (dox) showed cell-specific anticancer efficacy29
(Fig. 5). The addition of dox only (white bars) showed non-cell-
specific anticancer efficacy because dead cells were detected in
both HeLa and MCF-7 cells. Conversely, there was no anticancer
efficacy in either of the cells treated with LP encapsulating dox
(gray bars). However, [Z1907]2-BNC/LP encapsulating dox (black
bars) showed anticancer efficacy in only HeLa cells. These results
indicated that [Z1907]2-BNC/LP could deliver drugs to EGFR-
expressing cells and release drugs from the endosome to the cyto-
sol with the retention of pharmaceutical activity.In this study, we developed a carrier targeting EGFR-expressing
cells by displaying the dimer of Z955 or Z1907 with specificity to
EGFR on the surface of BNC. As a result, the specific binding of both
[Z955]2-BNC and [Z1907]2-BNC to EGFR-expressing cells was con-
firmed. Furthermore, Z1907 is reported to have an affinity to EGFR
that is higher than that of Z955, and it showed a binding ability to
EGFR-expressing cells that also was higher than that of Z955 in the
case of the BNC surface display. Additionally, since we could grant
the ability of endosomal escape to a [Z1907]2-BNC by forming a
complex carrier with LP, [Z1907]2-BNC/LP would be a useful drug
delivery carrier for various cancer cells. This study indicated that
we could develop an affibody-displaying BNC with a high affinity
for various targeted cells by displaying the dimer of an affibody
on the BNC surface.
Fig. 4. Fluorescence images of HeLa cells treated with [Z1907]2-BNC/LP complexes encapsulating calcein (100 lM). Scale bars: 50 lm.
Fig. 3. Time course of Alexa Fluor 488-labeled [Z1907]2-BNC into HeLa and MCF-7 cells. (final concentration: 9 lg/ml, scale bars: 50 lm).
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Fig. 5. Anticancer efficacy of [Z1907]2-BNC/LP in HeLa and MCF-7 cells. White, gray
and black bars showed dead cell percentage of HeLa and MCF-7 cells treated with
doxorubicin (dox), LP encapsulating dox (LP) and [Z1907]2-BNC/LP encapsulating
dox ([Z1907]2-BNC/LP), respectively.
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